Sign in
Taking peoplePhase 4

Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)

Key facts

Who runs it
CSL Behring
Where
Denmark3 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 4
People taking part
270 people, planned
Started
29 Sept 2026
Expected to end
15 Sept 2033
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CE1226
Record updated
16 October 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Age greater than or equal to (>=) 18 and less than or equal to (<=) 65 years at the time of providing written informed consent
  • Confirmed diagnosis of emphysema related to AATD with either the PiZZ, PiZ(null), or Pi(null/null) genotype with documented serum AAT levels less than (<) 11 micrometer (μM) (or < 50 mg/dL [milligram/deciliter]) at any time before the first administration of CE1226 on Day 1 (Baseline)

Who cannot take part

  • Participants should not have acute illness or pulmonary exacerbation within 6 weeks before the first administration of CE1226 on Day 1 (Baseline)
  • Participants should not have previously received gene therapy for AATD at any point
  • Participants with liver disease secondary to AATD

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density decline in alpha-1 antitrypsin (AAT) deficient participants over 3 years as compared with the marketed dose 60 milligrams per kilogram (mg/kg).

The 3 groups in the trial

  • CE1226 low doseExisting treatment, for comparison

    CE1226 at low dose.

    Treatment: CE1226

  • CE1226 medium doseTreatment being tested

    CE1226 at medium dose.

    Treatment: CE1226

  • CE1226 high doseTreatment being tested

    CE1226 at high dose.

    Treatment: CE1226

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered Over 3 Years as Longterm Maintenance Therapy in Adult Subjects With Emphysema Related to Alpha1 Antitrypsin Deficiency
Criteria questions
Built from NCT07326592, who can take part
Record updated
16 October 2026